Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + docetaxel + lobaplatin + nab-paclitaxel
- Development stage
- Preclinical
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of anlotinib (a multi-target tyrosine kinase inhibitor that inhibits angiogenesis-related kinases such as VEGFR, FGFR, PDGFR, and c-Kit), docetaxel (a taxane chemotherapy agent), lobaplatin (a platinum-based chemotherapy agent), and nab-paclitaxel (an albumin-bound formulation of paclitaxel). While clinical data exists for anlotinib plus docetaxel in non-small cell lung cancer (NSCLC), showing improved progression-free survival compared to docetaxel alone, specific information about the four-drug combination is not available in the provided search results.
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)DNAVEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on anlotinib + docetaxel + lobaplatin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + docetaxel + lobaplatin + nab-paclitaxel.